Stockholm Stock Exchange: Analysts identify defensive stocks and growth potential

Analysts are identifying specific opportunities on the Stockholm Stock Exchange as certain high-valuation companies continue to rise while others become more attractively priced.

In the pharmaceutical sector, AstraZeneca is noted for its strong fundamentals and expected earnings growth despite recent price fluctuations following rumors of potential merger discussions. Analysts highlight its robust research portfolio and upcoming Phase 3 clinical results as key drivers.

In the defense sector, MilDef has received a buy recommendation from Swedbank SB1 Markets. Despite a 65 percent rise in share price this year, analysts argue the company is undervalued compared to peers, citing an expected annual adjusted EBITDA growth of 53 percent between 2025 and 2028 and a record-breaking order book.

Additionally, the company Duni is highlighted as a defensive option with a high expected dividend yield of approximately 7 percent. While logistics concerns have pressured its price, major shareholders have been increasing their positions.